Kiora Pharmaceuticals In-Licenses Late-Stage Oral Calpain Inhibitor KIO-401

Article summary

Kiora Pharmaceuticals has secured exclusive development and commercialization rights outside Asia for KIO-401, a late-stage neuroprotective therapy for central retinal artery occlusion (CRAO), from Senju Pharmaceutical.